Mayank Mamtani

Mayank Mamtani serves as senior managing director and group head of healthcare research for B. Riley Securities. He joined the firm's industry-leading equity research team in 2018 to focus on coverage of smid-cap biopharmaceutical companies developing therapeutics innovation in oncology, cardio-metabolic, neuro-ophthalmology, dermatology, and respiratory disease states. He was previously with Amgen, where he led the execution of numerous growth-focused corporate development initiatives, including conducting diligence on select M&A, licensing, and strategic collaboration ideas. Mr. Mamtani also served on several CEO staff projects, such as developing therapeutic area strategies with business leaders for annual board of director communications and creating an organization-wide molecular diagnostics capability; most recently, he was responsible for commercial strategy and operations for two targeted oncology brands grossing more than $1.5 billion in U.S. sales. Prior to Amgen, Mr. Mamtani was in equity research at Leerink Partners covering more than 25 large- and smid-cap biopharma companies with commercial and development therapeutics. He also served as a life sciences competitive strategy consultant focused on oncology therapeutics. He was originally trained through internship/co-op industry programs at AstraZeneca and GSK Oncology, as well as a life sciences VC firm.

Mr. Mamtani holds an M.S. in biotechnology management from Carnegie Mellon University and a B.E. in biotechnology from Delhi College of Engineering.